Novartis AG ADR (NVS)vsProcessa Pharmaceuticals Inc (PCSA)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
PCSA
Processa Pharmaceuticals Inc
$2.70
+1.89%
HEALTHCARE · Cap: $7.93M
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 24.7% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PCSA
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Intrinsic value data unavailable for PCSA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : PCSA
The strongest argument for PCSA centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : PCSA
The primary concerns for PCSA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
PCSA carries more volatility with a beta of 0.89 — expect wider price swings.
NVS is growing revenue faster at 2.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 23/100), backed by strong 24.7% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Processa Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients with unmet medical needs in the United States. The company is headquartered in Hanover, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?